Open-Label Rollover Study of Cenicrivoc for the Treatment of Liver Fibrosis in Adult Subjects with NASH Read more about Open-Label Rollover Study of Cenicrivoc for the Treatment of Liver Fibrosis in Adult Subjects with NASH
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of PF-05221304 Administered Daily for 16 Weeks... Read more about A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate Safety, Tolerability and Pharmacodynamics of PF-05221304 Administered Daily for 16 Weeks...
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH Read more about A Phase 2, Randomized, Double-Bling, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with NASH
